Dermatology

Latest News

OX40 Antagonist Amlitelimab Meets Primary and Secondary Endpoints in Late-Stage COAST-1 Trial / image credit Sanofi logo ©Florence Plot/stock.adobe.com
OX40 Antagonist Amlitelimab Meets All Primary and Secondary Endpoints in Phase 3 Atopic Dermatitis Trial

September 11th 2025

Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.

Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis / image credit atopic dermatitis ©designua/stock.adobe.com
Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis

August 27th 2025

AAD Atopic Dermatitis Treatment Update: A Q&A With Linda Stein Gold, MD
AAD Atopic Dermatitis Treatment Update: A Q&A With Linda Stein Gold, MD

August 27th 2025

Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose / image credit: ©New Africa/AdobeStock
Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose

August 25th 2025

Upadacitinib Shows Significant Hair Regrowth in Second Phase 3 Trial for Severe Alopecia Areata
Upadacitinib Shows Significant Hair Regrowth in Second Phase 3 Trial for Severe Alopecia Areata

August 22nd 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.